vevoctadekin

Vevoctadekin is a recombinant engineered form of human interleukin-18 (IL-18), specifically designed to be resistant to inhibition by the endogenous IL-18 binding protein ("decoy-resistant"). This modification enhances its ability to stimulate immune responses within the tumor microenvironment. Vevoctadekin acts as an immunostimulatory cytokine therapy and is being developed for the treatment of a broad range of solid tumors—including melanoma, renal cell carcinoma, triple-negative breast cancer, non-small cell lung cancer, merkel cell carcinoma, urothelial cancer, gastric cancer, cervical cancer, small-cell lung cancer, cutaneous squamous cell carcinoma, platinum-resistant ovarian cancer, endometrial cancer, esophageal cancer—as well as hematologic malignancies such as relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), B-cell lymphoma and multiple myeloma. The drug is administered subcutaneously and is currently in Phase 1/2 clinical trials. Vevoctadekin has also been studied in combination with pembrolizumab (an anti–PD-1 antibody) for enhanced antitumor activity[1][2][3][4][5][9].

Brand names

vevoctadekin

Other names

Interleukin 18 (recombinant human mutein clone ST-067)decoy-resistant IL-18